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Should oncologists be responsible for monitoring  
post-treatment follow-up in cancer patients?
Barbara Radecka1, Joanna Streb2
With increasing cancer rates, a steady rise is also observed in the numbers of such patients being followed-up after 
their treatment. This aspect of healthcare embraces cancer patients recovering from radical treatment, post-palliative 
treatment and frequently those patients who have exhausted the possibilities of specialist treatment. Controversies 
are ever ongoing about who should be responsible for monitoring post-treatment follow-up. Bearing in mind the 
limited numbers of specialists in clinical oncology, radiotherapy and cancer surgery, relative to GP specialists, the roles 
of GPs should be more boldly and clearly defined regarding the delivery of healthcare to cancer patients. Developing 
proficient ‘healthcare models’ based on collaboration between oncologists and GPs is thereby required. This article 
presents the arguments for justifying such a solution. 
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Introduction
Monitoring cancer patients recovering during post-
treatment forms a significant part of delivering compre-
hensive healthcare in oncology. Such surveillance embraces 
patients after radical treatment, those having completed 
palliative therapy and often patients who have exhausted 
the means of specialist treatment. Coupled with the grow-
ing numbers of cancer patients, is a constant increase in 
cancer survivors. The advances made in the early detection 
of cancer, along with specialised therapy have led to lasting 
remissions or complete cures. Cancer survivors are in any 
case constantly monitored when their treatment is ended 
for over several to even dozens of years. The numbers of 
convalescents registered for monitoring by oncologists, 
as well as by GPs are constantly rising, with only a few not 
taking advantage of such services [1]. With the passage of 
time after ending treatment, visits to oncologists become 
reduced whereas GPs are increasingly seen more often [1, 2]. 
Around one third of those monitored take advantage of 
both these options in parallel, with the rest mostly remaining 
under the care of an oncologist [3]. It should however be 
stressed that such evidence comes from studies that are by 
nature observational, retrospective or they are surveys, and 
therefore suffer from many limitations. Random sampling 
studies of patients are however lacking. 
The issue of post-treatment monitoring of cancer pa-
tients poses a serious challenge in the organisation and 
financing for all healthcare systems, no matter how they 
are set up and function, nor do they depend on the level of 
a country’s economic development. 
This situation has come about not merely by the in-
creased numbers of patients covered by these services but, 
inter alia, by the rising costs of diagnostic testing. It should 
be remembered that the healthcare required by conva-
lescing patients after radical treatment is in itself specific 
in nature (ie. observations aimed at establishing whether 
treatable relapses or other primary tumours occur and the 
diagnosing of late complications arising from cancer treat-
ment) as well as for patients ending palliative treatment 
(interventions aimed at improving the quality of life). The 
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problem thus arises on who should be responsible for the 
post-treatment monitoring of these cases.
Despite efforts over many years, no healthcare system 
has successfully addressed this issue. The most effective 
systems place onus on coordinating the services provided 
by the specialist and GPs as well as possibly specialist nurses. 
This becomes important insomuch that lifestyle recommen-
dations and preventative measures are usually somewhat 
different; if coming from the oncologist then these deal with 
cancer, but if from the GP, then other 21st century diseases 
are dealt with [4]. International Scientific Societies (ie. ESMO, 
ASCO and ACS) have attempted to agree a consensus for 
post-treatment monitoring of cancer patients, taking into 
account the disease characteristics and its treatment course 
although this can be difficult in some instances, because the 
appropriate scientific data can be lacking. It is important 
that such recommendations consider the type of healthcare 
system operating in a given country so that they can become 
incorporated into everyday practice [5]. 
Poland lacks a system of coordinated healthcare for can-
cer survivors. Such care is provided by oncologists or other 
specialists involved in cancer treatment (e.g. radiotherapists, 
laryngologists, urologists, haematologists etc.). Thus, there 
exists an urgent need for creating a system based on the 
collaboration between specialists and GPs, with both sides 
mutually complementing each other. 
Arguments for making the oncologist 
responsible for monitoring
It is universally recognised that after intensive and usu-
ally long-lasting treatment for cancer, the patient undergoes 
monitoring by an oncologist where, apart from interviews 
and physical examination, additional testing is performed 
(laboratory and imaging tests). During treatment patients 
can often lose contact with their GPs, where their doctor 
now becomes the oncologist and all health issues are now 
dealt as part of specialised healthcare [6]. This creates 
a certain mental barrier for returning back to the healthcare 
provided by the GP when treatment ends, as the patient is still 
expecting healthcare to be delivered by the specialist [7, 8]. 
The patient expects that tests performed during follow-up 
will also lessen their anxiety about any possible relapse. 
Some studies indicate that patients have more confidence 
in specialists, and when specialists and GPs are compared, 
then patients tend to favour the former in respect of being 
more satisfied [9]. Nevertheless, there is plenty of evidence 
showing there are no significant differences in detection 
rates of relapses, quality of life during follow-up, depression 
and anxiety between oncologists/cancer surgeons when 
compared to GPs [4, 10].
It should be noted that GPs does not often see a cancer 
patient. According to the National Cancer Registry from 
2013, there are around 900,000 people in Poland diagnosed 
with cancer, with almost half of these having been diag-
nosed within the last 5 years [11]. Under the conditions in 
Poland, it is also noteworthy that on average a GP has around 
2,000–2,500 patients under their care, where of these, sta-
tistically speaking, one can expect 50–60 persons who had 
been diagnosed with cancer. Taking into account the mor-
bidity (ie. around 160,000 new cases annually), the GP has 
a chance for diagnosing 8–10 cancers and to confirm 4–5 
deaths arising from cancer per year [11]. Such outcomes do 
not help GPs in acquiring experience for delivering health-
care to cancer patients. 
This problem is already apparent at the undergradu-
ate level, where the role of the oncologist is marginalised 
and the study time devoted to this subject is low together 
with the commonly met attitude that oncology can any-
way be taught in almost any clinic or any other clinical 
departments. At the post-graduate level things are little 
better, where specialisations in internal medicine or fam-
ily medicine do not include an oncology placement. A GP 
therefore does not get the opportunity for gaining the 
relevant knowledge about oncology, and yet cancer is the 
second highest cause of mortality in Poland. This results 
in low detection rates of early stage cancer and omissions 
made in diagnoses.
Another doubtful issue is whether the knowledge of 
complications after cancer treatment is adequate. Studies 
indicate that GPs can very rarely diagnose complications af-
ter chemotherapy and likewise polyneuropathy, pulmonary 
fibrosis, heart failure, early menopause or relapsed tumours 
[12]. Oncologists do not provide patients with informa-
tion in their discharge notes for GPs concerning the risk of 
complications; patients are in fact not practically observed 
with such events in mind. In cancer survivors, invariably of 
young age, there are also elevated risks of disorders arising 
in the metabolism of adipose tissue (increased production of 
pro-inflammatory adipokins) and muscle (increased insulin 
resistance) and endocrine disorders (pituitary-hypothalamic 
axis damage and deficiencies in growth hormone, oestro-
gens, testosterone or thyroid hormones [13]. At the same 
time, GPs and some specialists in other areas, have insuf-
ficient understanding of patient needs during their conva-
lescence. Many myths are at fault here, such as adverse reac-
tions to changes in the weather to rehabilitation. Although, 
as a consequence, cancer treatment reduces physical activity 
and fitness and that physical rehabilitation (at health spa 
conditions) improves fitness and lessens feeling of fatigue, 
doctors reluctantly recommend rehabilitation and even 
consider this to be counter-productive.
The purpose of follow-up after cancer treatment is also 
to analyse long-term outcomes in treatment through sur-
vival times and general health status. Long-term follow-ups 
of patients supply a broad knowledge-base on this topic. 
This particularly applies to persons who had suffered illness 
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at childhood and, on becoming cured, had been followed-
up for 20, 30 or more years [14]. 
All this goes to show that follow-ups cannot be con-
ducted without an oncologist being present. It should be 
emphasised that testing schemes should be individually 
tailored, especially in patients undergoing palliative treat-
ment in whom further curative treatment is possible. 
Arguments for making the GP  
responsible for monitoring
With the steady increase in cancer morbidity and the 
growing numbers of post-treatment cancer patients, the 
question arises as to who should be responsible for moni-
toring the follow-up. Given the small numbers of special-
ists in clinical oncology, radiotherapy and cancer surgery 
in Poland, when compared to GP specialists, the defined 
roles of GPs should be put forward more boldly in deliver-
ing healthcare to cancer patients. Notwithstanding the 
conviction that post-treatment patients are better off being 
monitored by an oncologist, it should be clearly stated that 
there are insufficient numbers of both specialist oncology 
centres and oncologists in Poland; at present there are 700 
clinical oncologists and 29,000 GPs. The aforementioned 
data from the National Cancer Registry, along with the 
observed everyday practice of oncologists indicate that 
specialist out-patient healthcare in oncology centres is 
and will be increasingly burdened by the requirements for 
undertaking follow-ups. 
It is noteworthy that patient follow-up after radical can-
cer treatment is, above all else, intended to discover if there 
have been any relapses or that the state of any subsequent 
primary tumour found allows treatment to re-commence; 
such procedures can be undertaken by GPs. Post-treatment 
patients commonly expect to undergo regular imaging tests 
to ‘assure themselves that there is no disease progression’. 
This applies to both those who had undergone radical treat-
ment as well as those after palliative therapy. An important 
aspect of follow-up is to maintain an appropriate balance 
between patient expectations and a realistic assessment of 
the value that any given diagnostic tests may bring; as well 
as the costs involved. It is also important to recognise that 
there is a lack of clear, unequivocal and accepted standards 
in follow-up which make doctors, whether in oncology cen-
tres or GPs, vulnerable to being accused of failing to provide 
adequate care [5]. 
Many cancer survivors have experienced various co-
morbidities and as a result they regularly see their GPs be-
cause waiting times to specialist clinics are much longer. It is 
the GP who has full knowledge on the patient’s health status 
and is responsible for the entire treatment of co-morbidities; 
knowing ‘his/her’ patients well. Delivering such healthcare 
may equally consist of monitoring during post-cancer treat-
ment follow-up. It is the GP who is more often likely to see 
the patient than the specialist to conduct interviews or 
physical examinations. 
Even though specialist teaching in family medicine 
does not include placement at an oncology department, 
nonetheless oncology constitutes part of the placement 
for palliative care and in hospices, where future GPs will 
have had experience of cancer patients. Within the remit 
of specialist teaching for family medicine, doctors also take 
part in lectures and seminars on oncology. Indeed, basic 
training in family medicine takes 4 years for a doctor not 
yet specialised, where they will on numerous occasions 
come into contact with cancer patients. Physicians working 
as GPs can take advantage of the annex to their contract 
with the NFZ (Polish National Health Fund) regarding list-
ings of permissible laboratory and imaging tests, but this 
list insufficiently covers follow-up monitoring post cancer 
treatment. In accordance with this contract, GPs are not al-
lowed to issue referrals for computer tomography (CT) scans, 
mammographies or breast ultrasound. This severely limits 
any follow-ups after adjuvant therapy for breast or colonic 
cancer and thereby obliges the patient to see a specialist. 
A simple legal amendment could clearly alter this, since 
the aforementioned cancers (i.e. breast and colon) belong 
to the most commonly occurring cancers in Poland and 
that most cases are treated radically which requires many 
years of follow-up. 
When making diagnoses and in treating complications 
after cancer treatment, both GPs and oncologists seek con-
sultations with other specialists that may include neurolo-
gists, cardiologist, endocrinologists or orthopaedicians and 
in any case the healthcare delivered by the GP or oncologist 
should be comparable. Studies indicate that GPs are capable 
of carrying out follow-ups after cancer treatment in a timely 
and patient-safe fashion [15, 16]. 
Conclusions
Appropriate management of cancer survivors follow-
up poses a serious challenge in terms of organisation and 
financial resources to the healthcare system, above all else 
because the number of such patients is constantly rising 
and where they feel completely lost in this system. Studies 
have indicated that one third of cancer survivors don’t know, 
who actually bears responsibility for their healthcare [9]. The 
experiences of many countries show that the most effective 
solutions are those that emphasise coordinated healthcare 
between the specialist and GP (including the family doctor) 
together with perhaps specialist nurses. Poland needs to 
urgently create a system of coordinated healthcare in this 
field embracing equally the oncologist as well as the GP.
This article presents a list of arguments that justify such 
a solution. The Polish legislation popularly known as ‘The 
Oncology Package’ assumes that patients treading ‘the path 
of rapid diagnostics and cancer treatment’ will after its con-
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clusion/termination return to being under the healthcare 
of their GP [17]. The proposed solution in the legislation 
is unfortunately not supported by any changes in the fi-
nancing of post cancer treatment follow-up. It is difficult to 
expect that this care will be taken up by GPs. In practice, the 
patient however remains under the care of the oncologist, 
where cancer centres are still wrestling with the so-called 
problem of ‘overspending’ regarding specialist out-patient 
healthcare of which patient visits and follow-up testing 
forms a significant part. Creating a system of coordinated 
healthcare also requires introducing changes in the under- 
and post-graduate education of doctors. One of the main-
stays of such a system could become the nurse. Engaging 
this group of professionals has proved successful in diabetic 
care, where nurses have made a great contribution, inter 
alia, in educating patients. It is worth taking advantage of 
these solutions, particularly since the law has widened the 
range of nurse competencies, for instance in the issuing of 
prescriptions for medicines.
Within recent years, dynamic developments in telemedi-
cine have been witnessed. In some specialisations, this has 
enabled effective monitoring, at a distance, of the patient’s 
health status which is particularly important at a time when 
the population is aging. Various types of tele-monitoring are 
currently under investigation that use electronic devices and 
even social media, which include applications for cancer 
patients. This phenomenon is worth observing with a view 
for introducing such solutions in Poland.
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